7:04AM Compugen discloses focused target discovery program for antibody-drug conjugate cancer therapy (CGEN) 5.26 : Co disclosed the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers. This second program follows Compugen's successful initial focused discovery program for novel immune checkpoint proteins, a number of which have been incorporated in the Co's Pipeline Program as Fc fusion protein drugs for immunology and/or as therapeutic targets for monoclonal antibody drugs for cancer immunotherapy.
Market Data 
Markets 
AI
